February 19, 2020Journal of Clinical Oncology
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Authors
Discussion
Loading...
Member takes
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Tannir et al. (2020) studied this question.